[ad_1]
North American Modern says that it can stay for six months at -20ºC and 30 days under normal refrigeration conditions, with an efficiency of 94.5%. The European Commission advances with a contract.
The modern American vaccine against COVID-19 has the advantage of being able to be transported and stored for six months at minus 20 ° C, the temperature of most domestic or medical freezers, and withstand up to 30 days under normal conditions. refrigeration after defrosting, the pharmaceutical company announced, citing an efficiency of 94.5%. By the end of the year, he hopes to have around 20 million doses to distribute. The European Commission is already moving forward with a new contract.
At the forefront of the vaccine race, Moderna presented interim data that puts it ahead of Pfizer, whose vaccine must be stored at -70 ° C and is 90% efficient. Furthermore, Moderna’s vaccine is expected to “stabilize at standard refrigeration temperatures of 2 ° to 8 ° C for 30 days, an evolution of the previous estimate of seven days.” And “dilution will not be necessary” before it is administered, the company explains.
In a statement, it details that, in the third phase of the clinical trial, 95 confirmed cases of the disease were identified: five had received the vaccine and 90 were from the group that received the placebo, in which 11 cases of serious disease were identified.
“This positive interim analysis has given us the first clinical validation that our vaccine can prevent covid-19 disease, including serious illness,” said Stéphane Bancel, Moderna CEO.
The US company will present, “in the coming weeks”, a request for authorization of emergency use to its federal agency. It will do the same with international agencies and maintains its goal of producing between 500 million and one billion doses of mRNA-1273 in 2021.
The European Commission has already announced that it is working on the sixth pre-purchase contract, this time with Moderna.
Juan Andrés, director of operations and quality, points out that the conditions found in the study will allow “an easier distribution and greater flexibility of vaccination on a larger scale, both in the United States and in the rest of the world.”
Optimistic coast
Despite welcoming the “good candidates”, the director general of the World Health Organization warned that a vaccine “alone will not be enough” to defeat the pandemic. “It will complement the other tools, it will not replace them,” said Tedros Adhanom Ghebreyesus.
António Costa has pointed out that the “effort” made by the Portuguese has “a light at the end of the tunnel.” “We still don’t know the length of the tunnel. Either for months or a year. We certainly know that in the next year we will have a vaccine available,” he said.
The price will not weigh
For her part, the general director of Health, Graça Freitas, said that, “in Portugal, surely it will not be the price that defines which vaccine will be used.”
To JN, the Directorate General of Health assured that “everything possible is being done to guarantee the correct and timely distribution of vaccines” and that “they are also considering the issues of the cold chain.” “All sites are being considered for vaccination. As with the influenza vaccine, the autumn-winter plan considered the possibility of using other structures that can be selected for this purpose, ”he explained.
[ad_2]
